Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| Aperture Health, Inc. (NASDAQ: APRE) | Delayed: 0.52 -0.02 (3.7%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.54 | 52 Week High | $0.08 | |||
| Open | $0.53 | 52 Week Low | $0.00 | |||
| Day High | $0.55 | P/E | N/A | |||
| Day Low | $0.50 | EPS | $0.00 | |||
| Volume | 89,184 | |||||
